BMSSC
DNLI icon

B. Metzler seel. Sohn & Co’s Denali Therapeutics DNLI Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.89M Hold
112,300
– – 0.03% 347
2026
Q1 		$2.16M Hold
112,300
– – 0.02% 368
2025
Q4 		$1.84M Buy
+112,300
New +$1.9M 0.02% 427

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

B. Metzler seel. Sohn & Co's DNLI Position: Q2 2026 in Review

B. Metzler seel. Sohn & Co held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 112,300 shares worth $2.89M. The position accounts for 0.03% of the portfolio, ranked #347.

B. Metzler seel. Sohn & Co first reported a position in DNLI in Q4 2025 and has held it in 3 quarters since. 149 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • B. Metzler seel. Sohn & Co held 112,300 shares of Denali Therapeutics worth $2.89M as of Q2 2026.
  • B. Metzler seel. Sohn & Co left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up 0.03% of B. Metzler seel. Sohn & Co's portfolio in Q2 2026, its #347 holding.
  • B. Metzler seel. Sohn & Co first reported a position in Denali Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 149 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q2 2026, filed 11 Aug 2026.